Spirulina and the Cyclin D/CDK4–Rb Axis: G1/S Cell Cycle Gating and Anti-Proliferative Mechanisms

Cyclin D Induction: Mitogens, PI3K, and RAS/ERK

Cyclin D proteins (D1, D2, D3—encoded by CCND1, CCND2, CCND3) are the rate-limiting licensing factors for entry into the S phase of the cell cycle. Unlike the mitotic cyclins A and B, which oscillate sharply, Cyclin D levels are set continuously by extracellular mitogenic signals and fall quickly when those signals are withdrawn. The two canonical upstream inducers are the RAS–RAF–MEK–ERK cascade and the PI3K– Akt–mTORC1 axis. ERK phosphorylates and stabilises the Cyclin D1 protein at Thr286 via GSK-3β inhibition: normally GSK-3β phosphorylates Thr286, flagging Cyclin D1 for CRM1-mediated nuclear export and proteasomal destruction; when ERK activates p90RSK or Akt inhibits GSK-3β, Thr286 phosphorylation is suppressed and Cyclin D1 accumulates in the nucleus. mTORC1 independently promotes CCND1 mRNA translation via S6K1 and 4E-BP1 phosphorylation, so that both arms of growth-factor signalling converge on Cyclin D protein abundance.

Transcriptional induction of CCND1 by NF-κB (κB sites at –968 and –910 in the human promoter) and by c-Myc (E-boxes) adds a third layer of control, connecting inflammatory and oncogenic inputs to cell-cycle entry. In many cancer types, this transcriptional route is constitutively active and accounts for the near-universal Cyclin D1 overexpression seen in breast, head-and-neck, and colorectal cancers.

The CDK4/CDK6 Holoenzyme and Rb Phosphorylation

Cyclin D binds and activates either CDK4 or CDK6, forming a holoenzyme whose principal substrate is the retinoblastoma tumour suppressor protein Rb (RB1). In its hypophosphorylated, active form, Rb binds and represses E2F transcription factors (E2F1–3a) that drive expression of genes required for S-phase entry: CCNE1/2 (Cyclin E), CDC25A, DHFR, thymidylate synthase, and the MCM helicase loader subunits. CDK4/Cyclin D phosphorylates Rb at Ser780 and Ser795 in a partial, initiating phosphorylation; subsequent CDK2/Cyclin E action completes Rb hyperphosphorylation at additional sites (Ser807/811, Thr821, Thr826), fully dissociating E2F and triggering the G1/S transcriptional programme.

Once the Rb–E2F brakes are fully released, Cyclin E/CDK2 drives the cell past the restriction point—a point of no return after which S-phase progression becomes mitogen-independent. This irreversibility is enforced by the positive feedback of E2F-driven Cyclin E transcription, making the G1/S transition a bistable switch. Targeting CDK4 or CDK6 (as the approved drugs palbociclib, ribociclib, and abemaciclib do) restores Rb's repressive grip over E2F and re-establishes G1 arrest in Rb-intact tumours.

CDKI Proteins: p21, p27, and the INK4 Family

Cyclin-dependent kinase inhibitors fall into two structurally and functionally distinct families. The CIP/KIP family—p21 (CDKN1A), p27 (CDKN1B), and p57 (CDKN1C)—inhibit multiple CDK/Cyclin complexes, including CDK4/D and CDK2/E, by inserting an inhibitory loop into the CDK active site. p21 is directly transcribed by p53 in response to DNA damage, making it the primary mediator of p53-dependent G1 arrest. p27 accumulates under anti-mitogenic signals (TGF-β, contact inhibition, nutrient deprivation) and is degraded by the SCF–Skp2 E3 ligase complex when mitogens are present; high Skp2 and low p27 is a marker of aggressive cancer. The INK4 family—p16 (CDKN2A/INK4A), p15 (CDKN2B/INK4B), p18 (CDKN2C), and p19 (CDKN2D)—specifically inhibit CDK4 and CDK6 by an ankyrin-repeat mechanism that prevents Cyclin D docking. p16/CDKN2A is the most frequently inactivated tumour suppressor gene in human cancer after TP53, deleted or silenced by methylation across dozens of cancer types. Its loss removes a key brake on the CDK4/Cyclin D axis, allowing constitutive Rb phosphorylation regardless of the extracellular mitogenic context.

How Spirulina Phycocyanin and AMPK Restrain Cyclin D in Cancer Models

Several mechanisms through which spirulina-derived compounds influence the Cyclin D/CDK4–Rb axis have been characterised in cell culture and rodent models. These apply specifically to contexts of dysregulated, hyperproliferative cells; the following should not be generalised to normal proliferating tissues without caveat.

Phycocyanin (PCB) suppresses NF-κB activity via IKKβ inhibition. In tumour cells where NF-κB drives CCND1 transcription, this directly reduces Cyclin D1 mRNA and protein abundance. In HeLa, MCF-7, and HepG2 cell models, PCB exposure (typically 0.1–0.5 mg/mL in vitro) produces measurable Cyclin D1 downregulation within 24–48 hours, accompanied by reduced Rb Ser780 phosphorylation and G1 accumulation on flow cytometry. The concurrent upregulation of p21 (likely through p53 stabilisation secondary to reduced survival signalling) amplifies the G1 arrest.

AMPK activation by spirulina—arising from its effect on the AMP/ATP ratio and from phycocyanin's inhibition of mitochondrial complex I uncoupling—suppresses mTORC1, reducing CAP-dependent translation of CCND1 mRNA via 4E-BP1 dephosphorylation. AMPK also directly phosphorylates p27 at Thr198, stabilising the protein against SCF–Skp2-mediated degradation. In models of nutrient stress and in rapamycin- sensitive cancers, this AMPK-p27 axis is a meaningful contributor to G1 restraint. Additionally, AMPK phosphorylates Rb at Ser804 in a CDK-independent manner, a modification associated with E2F repression that reinforces rather than supplants the CDK4-mediated circuitry.

Context Dependency: Normal Cells Versus Malignant Cells

A critical caveat is necessary here. The anti-proliferative effects on the Cyclin D/ CDK4–Rb axis described above have been observed predominantly in established cancer cell lines—cells that typically harbour constitutively active upstream oncogenes (KRAS, HER2, PI3K mutations) that drive Cyclin D to pathologically high levels. In these contexts, restoring normal CDKI tone or reducing excess Cyclin D1 is genuinely anti-tumorigenic. Normal proliferating cells—gut crypts, bone marrow progenitors, skin keratinocytes—require intact Cyclin D/CDK4 activity for homeostatic renewal, and broad CDK4/6 inhibition in these populations causes the haematological toxicities seen with CDK4/6 inhibitor drugs.

Spirulina at dietary doses is unlikely to produce the degree of CDK4 inhibition achieved by palbociclib or abemaciclib, and the existing cell-culture work uses concentrations that are hard to reconcile with plasma pharmacokinetics from oral supplementation. What is more plausible is a homeostatic tightening of the G1/S checkpoint—reducing the probability that transiently deregulated cells accumulate enough Cyclin D to override CDKI restraint—rather than a wholesale pharmacological block. This is a meaningful but more modest claim than the out-of-context statistics sometimes cited in supplement marketing.

Practical Takeaway

The Cyclin D/CDK4–Rb axis is one of the most clinically validated targets in oncology; the success of CDK4/6 inhibitors in HR-positive breast cancer has confirmed the pathway's druggability. Spirulina's contributions to this biology— NF-κB-driven CCND1 suppression by phycocyanin, AMPK-mediated mTORC1 inhibition reducing CCND1 translation, and p27 stabilisation—are mechanistically grounded and cell-culture-supported but should be understood as modulatory influences on a complex homeostatic system rather than as targeted cancer treatment. For healthy individuals, what these mechanisms may represent is a physiological tuning of the balance between cellular renewal and restraint, particularly relevant in tissues with high turnover where early dysregulation is most likely to occur.